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Abstract
Background: Based on their capacity to suppress immune responses, multipotent mesenchymal stromal cells (MSC) are
intensively studied for various clinical applications. Although it has been shown in vitro that the immunomodulatory effect
of MSCs mainly occurs through the secretion of soluble mediators, the mechanism is still not completely understood. The
aim of the present study was to better understand the mechanisms underlying the suppressive effect of MSCs in vivo, using
cells isolated from mice deficient in the production of inducible nitric oxide synthase (iNOS) or interleukin (IL)-6 in the
murine model of collagen-induced arthritis.
Principal Findings: In the present study, we show that primary murine MSCs from various strains of mice or isolated from
mice deficient for iNOS or IL-6 exhibit different immunosuppressive potential. The immunomodulatory function of MSCs
was mainly attributed to IL-6-dependent secretion of prostaglandin E2 (PGE2) with a minor role for NO. To address the role
of these molecules in vivo, we used the collagen-induced arthritis as an experimental model of immune-mediated disorder.
MSCs effectively inhibited collagen-induced inflammation during a narrow therapeutic window. In contrast to wild type
MSCs, IL-6-deficient MSCs and to a lesser extent iNOS-deficient MSCs were not able to reduce the clinical signs of arthritis.
Finally, we show that, independently of NO or IL-6 secretion or Treg cell induction, MSCs modulate the host response by
inducing a switch to a Th2 immune response.
Significance: Our data indicate that MSCs mediate their immunosuppressive effect via two modes of action: locally, they
reduce inflammation through the secretion of anti-proliferative mediators, such as NO and mainly PGE2, and systemically
they switch the host response from a Th1/Th17 towards a Th2 immune profile.
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Introduction
Multipotent mesenchymal stromal cells or mesenchymal stem
cells (MSC) are adult progenitor cells essentially isolated from bone
marrow or adipose tissue that can be rapidly expanded ex vivo in
large numbers. These cells are currently under investigation for
tissue engineering applications, in particular for bone and cartilage
repair, due to their potential to differentiate into the chondrocyte,
osteoblast or adipocyte lineages [1]. Besides their differentiation
properties, they may have a therapeutic value in other clinical
applications based on their capacity to limit scar formation
through anti-fibrotic properties, to prevent apoptosis, to stimulate
the regeneration of endogenous cells and to suppress the host
immune response (for review, see [2]). These immunosuppressive
effects have been shown to occur mainly through the secretion of
soluble factors. Among the possible mediators identified, indole-
amine 2,3-dioxygenase (IDO) [3], inducible nitric oxide synthase
(iNOS) [4–5], heme oxygenase (HO)-1 [6] as well as the secretion
of human leukocyte antigen (HLA)-G [7], transforming growth
factor (TGF)-b [8], interleukin (IL)-6 [9] and prostaglandin E2
(PGE2) [10] have been postulated to play a role in this process.
Depending on the species, immunosuppression mechanisms
displayed by MSCs may however differ. For instance, it has been
shown that murine MSCs do not possess IDO activity, whereas
human MSCs are devoid of iNOS (for review, see [11]). These
mechanisms result in the inhibition of the proliferation of CD4
+
and CD8
+ T cells, B lymphocytes, NK cells that has been mainly
shown in vitro but also in vivo in a number of experimental models
reviewed in [12].
The therapeutic efficacy of MSCs has been evaluated in
experimental autoimmune models, as well as in humans, to
prevent acute graft versus host disease (GVHD) [13]. Zappia and
collaborators were among the first to report the therapeutic
efficacy of MSCs in the experimental autoimmune encephalomy-
elitis (EAE) [14]. In this murine model of multiple sclerosis, the
administration of MSCs was found to decrease the clinical signs
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onset. However, no therapeutic effect was observed when the
injection occurred after disease stabilization. Similar results were
observed in a model of autoimmune diabetes, where MSC
injection promoted repair of pancreatic islets and renal glomeruli,
as well as mesangial thickening and reduction in macrophage
infiltration resulting in the prevention of pancreatic injury [15].
In collagen-induced arthritis (CIA), an experimental model of
rheumatoid arthritis (RA), conflicting results on the role of MSCs
have been reported. The first study on the use of MSCs in CIA
showed that allogeneic C3H10T1/2 cells did not exert a beneficial
effect on disease progression [16]. More recently, it has been
demonstrated that systemic injection of MSCs, engineered to
constitutively produce IL-10, after the recall of immunization
significantly reduced the arthritic symptoms, in contrast to the lack
of efficacy of wild type MSCs [17]. Since, it has been reported that
a single injection of primary MSCs prevented the development of
severe arthritis which was associated with a decreased level of pro-
inflammatory cytokines in the sera of MSC-injected mice and an
increased frequency of peripheral regulatory T (Treg) cells [18].
Similar results have been obtained in vitro and in vivo with human
adipose-derived stem cells (ADSC) that were shown to suppress T
cell responses through the generation and activation of antigen-
specific Treg cells [19, 20].
The aim of our study was to elucidate the in vivo mechanisms of
MSC-mediated immune suppression, in particular the role of IL-6,
PGE2 and NO, the function of which is poorly investigated in vivo,
and to evaluate their impact on T cell subpopulation in a model of
inflammatory autoimmune disease. Contrary to numerous previ-
ous reports, we used highly characterized MSCs, either syngeneic
or allogeneic and, MSCs deficient in the production of IL-6 or NO
that are proposed to play an important role in their immuno-
modulatory function.
Results
Primary MSCs from different mouse strains are
phenotypically and functionally different
Because most of the in vivo studies reported so far relied on the
use of poorly characterized murine MSCs, we decided to use a
population of BM-derived cells satisfying the criteria used for
MSCs. BM-derived cells, obtained from C57Bl6 or DBA1 mice,
were first selected by plastic adherence. A long process of culture
expansion was required to obtain a homogeneous cell population
with a spindle-shaped fibroblastic morphology and that lacked
hematopoietic markers. At this stage of culture, typically after
passage 6, both cell types derived from C57Bl6 and DBA1 mice,
named thereafter B6 and D1 MSCs respectively, were negative for
CD11b, CD14 and CD45 and possessed cell surface molecules
selectively expressed on MSCs including CD44 and Sca-1
(Fig. 1A). CD73 and CD105 were detected solely on D1 cells,
whereas CD90 was absent on both B6 and D1 cells. The MSC
nature of these cells was confirmed by their capacity to
differentiate into three lineages. Expression of lineage-specific
markers and components of extracellular matrix was respectively
quantified by RT-qPCR and immunohistochemistry. Both D1 and
B6 cells exhibited a similar potential to give rise to osteoblasts, as
shown by an increase in osteocalcine, alkaline phosphatase and
mineralization of the extracellular matrix; adipocytes, as shown by
the expression of peroxysome proliferator-activated receptor c,
fatty acid binding protein 4 and formation of lipid droplets as well
as chondrocytes, indicated by an enhanced expression of collagen
II and aggrecan, both at transcriptional and protein level (Fig. 1B).
As expected, these MSC populations exerted an inhibitory effect
on the proliferation of allogeneic splenocytes stimulated by
concanavalin A (Fig. 1C) which was dose-dependent, showing
approximately a 80% to 100% inhibition of splenocyte prolifer-
ation at the highest ratio tested of one MSC for two splenocytes.
The inhibitory effect was still detectable at the 1:20 ratio for B6
MSCs whereas it was abolished for D1 MSCs at this concentra-
tion, suggesting a different suppressive potential depending on the
mouse strain.
MSCs improve the clinical signs of arthritis during a
narrow therapeutic window
To determine in vivo the role of MSCs, we relied on the CIA
model of autoimmune rheumatoid arthritis. In this model,
conflicting results have been published on the therapeutic effect
of MSCs. Some of them may be explained by the use of MHC-
matched and -mismatched MSCs or the time of injection. First, we
investigated the effect of D1 or B6 MSCs when injected
intravenously in the DBA1 mice on day 18 and 24, 3 days before
and after the boost with collagen II. Injection of either allogeneic
B6 or syngeneic D1 MSCs resulted in a statistically significant
inhibition of the paw swelling (Fig. 2A, 2B). In these experiments,
both the clinical scores (mean score of 2.261 with B6 MSCs versus
4.261.4 in control and 3.560.9 with D1 MSCs versus 7.661.7 in
control) and the delay of disease onset (day 32.561.7 with B6
MSCs versus 28.260.9 in control and day 37.3360.7 with D1
MSCs versus 29.560.4 in control) were also statistically different.
Hence, both syngeneic and allogeneic MSCs were effective in
reducing the clinical signs of arthritis.
Next, we tested the effect of single or repeated injections of
syngeneic D1 MSCs performed at different time points. A single
MSC injection on day 18 delayed the arthritis onset (34.761.4
versus 3063.3 in CIA control mice), followed by a dramatic
increase of the paw swelling by day 38 (Fig. 3A). Injection of MSCs
on days 18 and 24 resulted in a significant reduction of the paw
swelling. However, no effect on the paw swelling was observed,
when the cells were injected on days 18 and 32. We therefore
confirmed that injection of MSCs apart from the boost was
beneficial for the treated mice. Repeated injection on days 18 and
24 was associated with a lower incidence (Fig. 3B), a delayed onset
(35.762.6 for d18- and d24-injected mice versus 3063.3 for CIA
control mice) and a significant reduction in the average of the
maximal paw swelling observed in each mouse during the course
of the disease (2.160.06 versus 2.660.15, respectively). The anti-
arthritic effect was further confirmed at the radiological and
histological level (Fig. 3C-D). In addition, a reduced infiltration of
immune cells into the joints was observed in mice treated with
MSCs on day 18 and 24, as shown by histological analysis (Fig. 3E).
We then evaluated whether MSCs were still effective when
administered after the boost. A single or repeated administration
of MSCs, either on day 24 or days 24 and 28 after disease onset,
did not yield significant reduction of the paw swelling. Compared
to control mice, repeated administration of MSCs even tended to
exacerbate arthritis (Fig. 3F). Together, our results show that,
independently of MHC haplotype, MSCs display a therapeutic
effect when administered during a narrow therapeutic window.
IL-6 is the central player in MSC immunomodulatory
properties
Among the mechanisms proposed to mediate the immunosup-
pressive function of MSCs, IDO, iNOS and COX2, through
PGE2 secretion, activities are consistently reported as the most
important mediators, at least in vitro [21]. IL-6 is another major
player as it has been proposed to regulate COX2 function as well
MSC Inhibit Arthritis via PGE2
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be involved in the generation of Treg cells. In order to better
evaluate the role of these factors, we derived MSCs isolated from
the bone marrow of C57BL6 mice deficient for iNOS or IL-6,
respectively named IL-6
2/2 and iNOS
2/2, and tested their
suppressive potential in vitro. IL-6
2/2 and iNOS
2/2 MSCs
displayed the same phenotypic characteristics and differentiation
potential as wild type (wt) B6 MSCs (data not shown). Using a
proliferative assay, we found that iNOS
2/2 and IL-6
2/2 MSCs
were still able to inhibit the proliferation of allogeneic splenocytes,
albeit to a significantly lesser extent as compared to wt B6 and D1
MSCs (Fig. 4A). The addition of both iNOS
2/2 and IL-6
2/2
MSCs in the proliferative assay did not show any additive effect on
the reversion of immunosuppression (data not shown). The
immunosuppressive effect was not directly correlated to the
secretion of NO as all MSC populations secreted approximately
20 mMN O 2, except for iNOS
2/2 cells (Fig. 4B). NO secretion
however was only observed when MSCs were cocultured with
activated splenocytes. The secretion of NO2 was inhibited after
addition of the specific inhibitor L-NAME. Splenocytes or MSCs
did not express basal levels of IL-6. However, except for IL-6
2/2
MSCs, IL-6 secretion was induced when MSCs were stimulated by
activated splenocytes, whereas it was partly inhibited in presence
of the COX2 inhibitor indomethacin (Fig. 4C). Production of IL-6
by iNOS
2/2 MSCs was 5 fold lower than wt B6 MSCs. Secretion
of PGE2 was up-regulated by more than 300 fold when




secreted 2.5 and 80 fold less PGE2 than wt B6 MSCs (Fig. 4D).
Specificity of the PGE2 secretion was confirmed by the
neutralization of this production by indomethacin. The produc-
tion of PGE2 was positively correlated with IL-6 secretion and was
inversely proportional to the anti-proliferative effect of the MSCs.
This is further correlated by the observation that wt D1 MSCs
secreted lower levels of IL-6 and PGE2 and were less
immunosuppressive at a MSC:splenocyte ratio of 1:20 (Fig. 1C).
Finally, we checked that IDO was not expressed by murine MSCs,
both at the mRNA and protein level, as evaluated by RT-qPCR,
spectrophotometric assay and high performance liquid chroma-
tography (data not shown). These results suggest that whereas NO
is partly responsible for the anti-proliferative effect of MSCs, IL-6-
activated PGE2 secretion mainly participates in this function.
iNOS
2/2 and IL-6
2/2 MSCs partially suppress arthritis-
associated inflammation
We then compared in vivo the injection of iNOS
2/2 or IL-6
2/2
MSCs to that of wt B6 MSCs in the allogeneic CIA model. Both
deficient cell populations were less efficacious than wt MSCs in
decreasing the paw swelling of the arthritic mice and wt MSCs
were the only cell population able to significantly reduce the paw
swelling of treated mice (Fig. 5A). However, IL-6
2/2 MSCs, but
not iNOS
2/2 MSCs, were able to induce a significant reversal of
immunosuppression as compared to wt MSCs. We therefore
investigated whether MSCs were able to inhibit the T cell
proliferation and to differentially regulate the involvement of Th1
or Th2 lymphocytes. Irrespective of the nature of the injected
MSCs, the bCII-specific response was decreased as assessed by the
significantly lower bCII-specific proliferative responses of cells
isolated from spleen (Fig. 5B) and draining lymph nodes (DLN)
(data not shown). Concomitantly, the bCII-specific IgG1/IgG2a
ratio tended to be higher in MSC-treated mice sera than in CIA
control sera with no significant differences between groups of
MSC-treated mice (Fig. 5C). Serum IL-6, reflecting systemic
inflammation, also showed the tendency to decrease in all groups
of MSC-treated mice (Fig. 5D).
As naı ¨ve CD4
+ T cells can differentiate into Th1 or Th2 effector
cells displaying a distinct cytokine profile, cytokine production
levels were thus quantified in supernatants from non activated or
bCII-stimulated cells isolated from spleen and DLN. The
Figure 2. Immunosuppressive effect of syngeneic and alloge-
neic primary murine MSCs in the CIA model. A) Evaluation of the
severity of arthritis by measurement of the increase of the paw swelling
of CIA control mice or mice injected with syngeneic D1 MSCs on day 18
and day 24. Results are representative of two independent experiments.
B) Evaluation of the severity of arthritis following injection of allogeneic
B6 MSCs at d18 and d24. Results are representative of three
independent experiments (*: p,0.05).
doi:10.1371/journal.pone.0014247.g002
Figure 1. Phenotypic and functional characterization of primary murine MSCs. A) Immunophenotype of bone marrow-derived MSCs
isolated from C57BL/6 and DBA/1 mice. Cells were stained with antibodies against the indicated antigens and analysed by flow cytometry.
Representative histograms are shown in black and the respective isotype controls are shown as grey line and are representative of three experiments.
B) Differentiation potential of murine MSCs. The differentiation in the 3 lineages is shown by up-regulation of specific markers by RT-qPCR and
specific staining. Osteogenesis is characterized by the expression of osteocalcin (OC), alkaline phosphatase (AP) and Alizarin Red S positive staining in
differentiation medium (lower panel) versus proliferative medium (upper panel). Adipogenesis is characterized by the expression of peroxysome
proliferator-activated receptor (PPAR)-c; fatty acid binding protein 4 (aP2) and Oil Red O positive staining in differentiation medium (lower panel)
versus proliferative medium (upper panel). Chondrogenesis is characterized by the expression of collagen II (Col II) and aggrecan (Agg) and anti-
aggrecan positive staining on pellet sections (lower panel) versus unstained control section (upper panel). Results are representative of three
independent experiments. C) Immunosuppressive potential of murine C57BL/6 (left panel) and DBA/1 (right panel) MSCs. Allogeneic splenocytes
were incubated for three days with ConA without or with various ratios of MSCs. Results are expressed as the percentage of ConA-induced
proliferation which was assigned the value of 100%6 SEM (n=3; ***: p,0.005).
doi:10.1371/journal.pone.0014247.g001
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IFN-c secreted by splenocytes were unchanged in MSC-treated
mice as compared to CIA control mice, except for a significantly
higher level of IL-17 in IL-6
2/2 MSC-treated mice (Fig. 5E). In
contrast, a high secretion of the anti-inflammatory cytokines IL-5,
IL-10 and IL-13 was detected in spleen of MSC-treated mice as
compared to CIA control group, whereas TGF-b1 secretion was
not affected (Fig. 5E). Secretion of IL-10 and IL-13 was
significantly higher in IL-6
2/2-treated group than in wt MSC-
treated group, whereas IL-13 production was only increased in
Figure 3. Immunosuppression is dependent of the injection time of primary MSCs in experimental arthritis. A) Evaluation of the
increase of the paw swelling of CIA control mice or mice injected with syngeneic D1 MSCs at various time points. Results are expressed as mean
increase 6 SEM and are representative of three independent experiments. B) Incidence of arthritis evaluating the percentage of mice with a clinical
score .1 (see experimental procedures). C) Radiological score evaluated after X-ray examination on hind paws from mice after euthanasia as assessed
in experimental procedures. Results are expressed as the mean 6 SEM. D) Histological score evaluated on paraffin sections of hind paws stained by
hematoxylin-eosin as assessed in experimental procedures. Results are expressed as the mean 6 SEM. E) Representative photomicrographs of joints
from CIA control mice (left), or mice injected with MSCs on d18 and d24 (right). Magnification65. F) Evaluation of the paw swelling in CIA following
injection of D1 MSCs after disease onset. Results are representative of two independent experiments (Statistical analysis showed not significance
between groups).
doi:10.1371/journal.pone.0014247.g003
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2/2-treated mice. Locally, in the DLN, decreased IL-17, IFN-
c and increased IL-5, IL-10, IL-13 secretion was also observed
(data not shown). Taken together, all the immunological
parameters tested suggest that MSCs induced a switch of the
immune response towards a Th2 cytokine production profile both
at the local and systemic level.
The immunosuppressive effect of MSCs is independent
on Treg cell induction
To verify whether the suppressive effect of MSCs was
exclusively dependent on the induction of Th2 lymphocytes, we
looked for the induction of regulatory cells in spleen and DLN of









+ Treg cells has also been shown to be induced by
MSCs [23]. Approximately 12% of cells from spleen and 6% from
DLN and PBMC from mice injected or not with MSCs were
found to be CD4
+CD25
+Foxp3
+ Treg cells. This percentage was
not modified after the administration of MSCs irrespective of their
origin (Fig. 6A). Similarly, the percentages of CD8
+CD28
2 cells
(Fig. 6B) or CD8
+CD28
+ cells (approximately 3% in spleen and
0.2% in DLN) were not affected by MSC injection. Because
subsets of B lymphocytes or macrophages characterized by IL-10
secretion have been attributed a regulatory function, we
investigated whether such cell subsets were induced by MSCs.
The proportion of IL-10-producing F4-80
+ macrophages and
B220
+ B lymphocytes was approximately 1% and 50% respec-
tively, among cells from spleen and did not vary following MSC
treatment. Finally, the induction of T cell subsets is associated with
the up-regulation of subset-specific transcription factors. The
expression of transcripts for Foxp3 by Treg cells and GATA-3 by
the Th2 subset was thus assessed in splenocytes of the various
groups of mice by RT-qPCR. The expression level of GATA-3
tended to be higher in MSC-treated mice, independently of the
lack of expression of IL-6 or NO, as compared to the CIA control,
while Foxp3 levels remained unchanged between groups (Fig. 6C).
Altogether, the data confirmed that MSCs mediated a therapeutic
effect independently of the induction of Treg cell subset and was
associated with a polarization of the host immune response into a
Th2 profile, independently of IL-6 or NO secretion.
Discussion
The immunosuppressive effect of MSCs is of great interest for
the prevention of transplant rejection or graft versus host disease
[13,24]. Successful treatment has also been reported in mice with
experimental autoimmune diseases, such as CIA or EAE, the
animal models of human RA and multiple sclerosis, respectively
[14,18]. However, conflicting results on the mechanisms devel-
oped by MSCs to suppress inflammation are still under debate. In
this study, we relied on the use of MSCs isolated from naı ¨ve mice
and mice deficient for immunosuppressive molecules to investigate
the role of these factors in vitro and in vivo. The main results are i)
the differential suppressive effect between MSCs isolated from
different mouse strains is only partly dependent on NO and may
be mainly attributed to IL-6-activated pathways through PGE2
up-regulation, ii) MSCs display a local intra-articular suppressive
effect, in particular through the secretion of IL6-dependent PGE2
and iii) MSCs exert a systemic suppressive effect by mediating a
polarization of the host immune response towards a Th2 profile,
independently from Treg cell induction or NO and IL-6 secretion.
One important finding of our study is that efficient therapeutic
treatment of CIA relies on the injection of MSCs during a narrow
window of application (day 18 and 24) as injection of MSCs after
disease onset did not prevent the occurrence of arthritic signs.
Conflicting results on the therapeutic effect of MSCs have been
reported in the CIA model. We and others previously reported
that MSC injection failed to reduce arthritis severity [16,17,25,26],
in contrast to the results from two other studies that showed a
therapeutic benefit [18,20]. The discrepancy between these studies
may be related to the source of cells (cell lines versus primary cells)
Figure 4. In vitro evaluation of the immunosuppressive
potential of MSCs by quantification of soluble mediators.
A) Inhibition of T cell proliferation following co-culture with MSCs.
Allogeneic splenocytes (10
5 cells) were incubated for three days with
ConA and when indicated, 5610
4 wildtype (wt) C57Bl/6 or MSCs
isolated from iNOS
2/2, IL-6
2/2 knock-out C57Bl/6 mice or DBA/1 MSCs
were added. Results are expressed as the percentage of ConA-induced
proliferation which was assigned the value of 100% 6 SEM (n=3).
B) Quantification of NO2 secretion using a modified Griess reagent.
C) Quantification of IL-6 secretion by ELISA. D) Quantification of PGE2
secretion by ELISA. Levels of the various soluble mediators were
quantified in supernatants of the proliferative assays performed in A)
after stimulation with ConA. Parallel assays were performed on cells
incubated in the same conditions with the addition of inhibitors specific
for NO2 (L-NAME) or PGE2 (indomethacin; Indo). Results are expressed
as the mean of 3 independent experiments 6 SEM; p values referred to
ConA-activated samples (black histograms), if not indicated (*: p,0.05).
doi:10.1371/journal.pone.0014247.g004
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administration. A lack of efficacy of MSC treatment related to the
timing of administration has already been reported in a model of
GVHD [27]. The authors concluded that factors required for the
induction of the immunosuppressive activity of MSCs were not
present at the time of injection and that MSC activation was
notably dependent on the magnitude of IFN-c exposure. This is
also supported by in vitro results indicating that MSCs may behave
as antigen presenting cells in presence of low doses of IFN-c and
thus, rather exacerbate the immune response [28]. In RA
physiopathogenesis, TNF-a is the major player in disease onset
and in the CIA model, TNF-a secretion increases at day 20 to
peak at day 30 [29]. We have previously suggested that TNF-a
may inhibit the function of MSCs when the cells were injected on
day 21 [16]. Accordingly, it has been shown that TNF-a primarily
targets mesenchymal cells resulting in the development of chronic
inflammatory polyarthritis and the conditional expression of
TNFRI in these cells is sufficient to induce a fully arthritic
phenotype [30,31]. These studies therefore suggest that injected
MSCs may be activated by TNF-a and play a role in the
pathogenesis of arthritis. In the present study, the injection of
MSCs on day 18 is likely to prevent immune cell activation which
occurs at boost and in particular, to reduce the secretion of TNF-
a. As a result, the activation of endogenous or exogenous
mesenchymal cells by TNF-a will not take place, resulting in the
inhibition of arthritis development. Immunosuppression requires
the presence of MSCs for a time lag sufficient for immune cell
education. Indeed, migration of MSCs to target tissues and
secondary lymphoid organs where they are able to educate
immune cells is likely to be required for efficient therapy. This has
not been tested here but would require further investigation as the
role of chemokines has been reported to be necessary to the
Figure 5. Immunosuppressive effect of iNOS
2/2 and IL-6
2/2 MSCs in experimental arthritis. A) Evaluation of the severity of arthritis by
measurement of the increase of the paw swelling of control mice (CIA) or mice injected with wt MSCs, iNOS
2/2 or IL-6
2/2 MSCs at d18 and d24 (see
arrows). Results are expressed as mean increase 6 SEM and representative of three independent experiments (*: p,0.05 between wt MSC-treated
group and CIA group; #:p #0.05 between wt MSC-treated group and IL-6
2/2 MSC-treated group). B) T-cell proliferation assay using splenocytes (10
5
cells) from the various treated mice incubated with 1, 5 or 25 mg/ml of bCII. C) Determination of the ratio of the bCII-specific IgG1/IgG2a by ELISA in
mouse sera. Results are expressed as mean 6 SEM. D) Quantification of IL-6 by ELISA in the mouse sera. E) Quantification of cytokines secreted by
2610
6 splenocytes cultured in vitro without activation (dashed histograms) or stimulated with 10 mg/ml bCII (black histograms) for 24 h (IFN-c and
IL-17) or 48 h (others) by ELISA. Results are expressed as the mean 6 SEM (*: p,0.05; **: p,0.01; ***: p,0.005; NS: not significant).
doi:10.1371/journal.pone.0014247.g005
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Finally, a recent study demonstrated that MSCs can be polarized
into two acting phenotypes classified as MSC1 and MSC2. TLR4-
primed MSCs, or MSC1, mostly elaborate pro-inflammatory
mediators, while TLR3-primed MSCs, or MSC2, are mostly
immunosuppressive [32]. This study provides a possible explana-
tion to some of the conflicting reports on the immune modulating
properties of MSCs.
Figure 6. Induction of a Th2 cellular response after treatment with MSCs. A) Percentage of CD4
+CD25
+Foxp3
+ Treg cells in individual
spleen, pooled draining lymph nodes (DLN) and individual peripheral blood mononuclear cells (PBMC) from control CIA or MSC-treated mice at day
31. FACS analyses show CD25
+Foxp3
+ cells gated on CD4
+ T cells in the splenocyte population. B) Percentage of CD3
+CD8
+CD28
2 Treg cells in spleen,
DLN and PBMC from control CIA or treated mice at day 31. For DLN, cells isolated from all mice in each treated group were pooled resulting in
absence of SEM. Results are shown as representative dot plots for 1 mouse per group of mice (upper panel) and histograms in lower panel (% 6
SEM), representative of three independent experiments of FACS analyses. C) Relative expression of mRNA level of GATA-3 and Foxp3 transcription
factors to GAPDH mRNA in splenocytes using the formula 2
2DCt. Results are expressed as the mean 6 SEM (NS: not significant).
doi:10.1371/journal.pone.0014247.g006
MSC Inhibit Arthritis via PGE2
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from MHC haplotype since we obtained similar results using
syngeneic or allogeneic MSCs. However, previous studies relying
on the use of primary MSCs obtained using similar protocols as
the one used here, although in different animal models, have
shown that allogeneic MSCs may lose their suppressive effect in
vivo and, actually, will elicit an immune response from the host
[33,34]. To better correlate in vitro and in vivo data, we decided to
rely on fully characterized BM-derived primary MSCs which led
us to show here that MSCs obtained from different strains of mice
do not exhibit the same capacity to inhibit T cell proliferation in
vitro. D1 MSCs were less efficient in inhibiting T cell proliferation
than B6 MSCs. This was shown in proliferative assays using
various ratios of splenocytes versus MSCs and was confirmed using
quantitative assays for specific immunosuppressive mediators. This
effect was proportional to the levels of IL-6 and PGE2 secreted by
the various types of MSCs. Thus, D1 and IL-6
2/2 MSCs
produced the lowest levels of PGE2 and IL-6. The secretion of
PGE2 was enhanced proportionally to the expression levels of
IL-6 in both wt and iNOS
2/2 MSCs. Conversely, PGE2
inhibition by indomethacin partly inhibited IL-6 secretion by
MSCs. This feedback regulatory loop has already been reported in
other model systems [35]. The key role of PGE2 in MSC-
mediated immunosuppression is supported by results from a recent
study showing that PGE2 represents the key inhibitory mediator of
DC differentiation and maturation and as a consequence, of
reduced T cell activation [36]. Moreover, MSC-derived PGE2
was reported to act on macrophages, increasing their IL-10
secretion and reducing inflammation [10]. We have observed that
MSCs promote in vitro the secretion of IL-10 by macrophages. We
also showed that in vitro, iNOS
2/2 MSCs were less suppressive
than wt MSCs. However, these cells secreted lower levels of IL-6
and PGE2 as compared to wt MSCs, making it difficult to
appreciate the role of individual molecules. This finding was
consistent with recent results showing inhibition of IL-6 and PGE2
after inhibition of NO in cartilage [37]. IL-6 seems to be the
central player since it is induced by PGE2 [38] but IL-6 also
positively regulates both COX2 and iNOS activities [22,39].
Indeed, in absence of IL-6 both NO and PGE2 production are
reduced. In our model in vitro, NO secretion was however poorly
impaired by loss of IL-6. Therefore in vitro, we showed that
iNOS
2/2 MSCs exert a lower suppressive activity than wt MSCs.
Using IL-6
2/2 MSCs, we demonstrated that IL-6-dependent
PGE2 secretion is correlated with the immunosuppressive
activity of MSCs suggesting that PGE2 is the major mediator of
immunosuppression.
In the CIA model, we confirmed the role of IL-6 and PGE2
in the suppressive activity of MSCs since IL-6
2/2 MSCs exhibit-
ed the lowest suppressive effect and did not significantly reduce
the severity of arthritis as compared to wt MSCs. Decreased IL-6-
dependent PGE2 secretion could account for this effect as
observed in vitro through its role on T cell proliferation,
macrophage reprogramming or DC maturation [40,41,42]. Here,
the effect of MSC-mediated iNOS activity was marginal since
iNOS
2/2 MSCs behave similarly as wt MSCs. This result
differs from another study in the experimental model of GVHD
[5]. The authors however principally used MSC clones which
behave differently from populations since the clones did not
secrete PGE2. It could be hypothesized that the inability
of iNOS
2/2 MSCs to suppress immune responses may be
the result of their impaired function to secrete both NO
and PGE2 which may be mediators with complementary
immunosuppressive functions. Therefore, using for the first time
IL-6-deficient MSCs, we confirmed in vivo that MSC immuno-
suppression was mainly dependent on IL-6-activated signalling
pathways although this effect was partial and that, PGE2 is likely
to be the mediator acting downstream in the MSC-mediated
immunomodulation.
Surprisingly, the clinical differences observed using various
MSC types were not concordant with the biological responses
since the evaluation of local and systemic immune responses of
MSC-treated mice revealed similar profiles, irrespective of their
production of either NO or IL-6. We observed a decreased bCII-
specific T cell proliferative response, an increased bCII-specific
IgG1/IgG2a ratio and low levels of pro-inflammatory mediators,
as well as increased levels of anti-inflammatory cytokines in bCII-
primed T lymphocytes from spleen. All these parameters are
characteristic of a Th2 immune profile which was further
confirmed by the increase in GATA-3 mRNA levels in splenocytes
from MSC-treated animals. These data were not consistent with
those of a previous study indicating that secretion of IL-10 and IL-
4 was down-regulated [18]. In the latter study however, MSCs
were cultured in vitro with T lymphocytes isolated from immunized
mice and challenged with bCII for 2 days. Because a Treg cell-
dependent mechanism of suppression has been proposed in CIA










2 cells in spleen, DLN
and blood. No significant increase of these T cell populations was
observed and no changes in TGF-b1 secretion levels or in Foxp3
mRNA expression were observed in splenocytes, further suggest-
ing that no Treg cells were induced. The discrepancy between
previous results and those reported here may arise from the time
and route (intra-peritoneal versus intravenous) of MSC adminis-
tration leading to variable immune responses. Interestingly,
injection of CD4
+CD25
+ Treg cells did not alter bCII-specific
antibody secretion or T cell proliferative response while markedly
slowing CIA progression [44]. Our results demonstrating altered
bCII-specific T and B cell responses are not in line with the
hypothesis of Treg cell induction but are in concordance with this
last study. Lack of Treg cell induction by MSCs was also reported
in autoimmune enteropathy [45] and EAE [14]. In the latter
study, the authors detected a slight down-regulation of CD40 and
MHC class II molecules on DCs, suggesting that impaired co-
stimulation by DCs from treated mice could contribute to
peripheral T cell anergy. Alternatively, secretion of PGE2 by the
injected MSCs may impair the maturation of DCs and therefore
may account for a switch towards a Th2 immune response profile,
as already reported in previous studies [40,41,42]. Indeed, anti-
proliferative mediators such as NO and more importantly, IL-6-
dependent PGE2 may act locally by inhibiting the proliferation of
immune cells in the synovium thereby reducing local inflamma-
tion. Altogether, our results suggest that NO or PGE2 mediators
may act together to decrease local inflammation but that the main
effect of MSCs is likely on systemic immunity through a
polarization of the host immune response towards a Th2 cytokine
production profile.
This study demonstrates that MSCs might be used for
regulating inflammatory responses and could offer therapeutic
benefit in autoimmune diseases. Like Treg cells, MSCs migrate to
the joints where they can act locally inside the inflamed synovium
to decrease the proliferation and function of immune cells via the
secretion of inhibitory soluble factors. They can also act
systemically to suppress the host immune response through a shift
in the Th1/Th2 cell balance, indicating that MSC-induced
immune suppression is not mediated by a single or unique
mechanism. This may have important therapeutic applications far
beyond the field of autoimmune diseases.
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Isolation of stromal cells
MSCs from C57BL/6 or DBA/1 mice or from iNOS- or IL-6-
knock-out C57BL/6 mice were isolated from bone marrow (BM).
BM was flushed out from long bones and the cell suspension
(0.5610
6cells/cm
2) was plated in minimum essential medium
(MEM)-a supplemented with 10% fetal bovine serum (FBS)
(Hyclone, Thermo Fisher Scientific, Brebie `res, France), 2 mM
glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin
(Lonza, Levallois-Perret, France) and 2 ng/ml human basic
fibroblast growth factor (bFGF) (R&D Systems, Lille, France). At
sub-confluence, cells were collected, propagated at a density of
5,000 cells/cm
2 and used between passages 6 and 10.
Differentiation of MSCs
Differentiation of MSCs was induced by culture under specific
conditions for 21 days. For adipogenesis, MSCs were plated at
10
4 cells/cm
2 in complete Dulbecco’s modified Eagle’s medium
(DMEM)-F12 (Invitrogen) with 16 mM biotin, 18 mM panthotenic
acid, 100 mM ascorbic acid, 5 mg/ml insulin, 0.03 mM dexameth-
asone, 1 mg/ml transferring, 2 ng/ml triiodothyronine (T3) and
100 nM rosiglitazone (Sigma-Aldrich, Saint-Quentin Fallavier,
France). Formation of lipid droplets was visualized by Oil red O
staining on cells fixed by 3% glutaraldehyde for 1 h. For
osteogenesis and chondrogenesis, inductive conditions were
already reported [46]. Chondrogenesis was assessed by RT-qPCR
and immunohistochemistry on paraffin sections of pellets using a
1/50 dilution of anti-aggrecan antibody (Chemicon, Millipore,
Molsheim) and the "Ultravision detection system anti-polyvalent
HRP/DAB" kit (Lab Vision, Francheville, France). Sections were
counterstained with Mayer’s hematoxylin (Lab Vision) for 3 min
and mounted with Eukitt (Sigma-Aldrich). Osteogenic differenti-
ation of MSCs was assessed by RT-qPCR and extracellular matrix
mineralization detected as already described [46].
RT-qPCR analysis
TotalRNAwasextractedusingthe RNeasyminikit(QiagenS.A.,
Courtaboeuf, France). RNA (500 ng) was reverse transcribed using
the Multiscribe reverse transcriptase and PCR was done with the
GeneAmpH RNA PCR Core Kit using the "Assays-on-Demand"
gene expression assays (Applied Biosystems, Courtaboeuf, France)
ontheLightcycler480(RocheAppliedSystems,Meylan).Contentof
cDNAsampleswasnormalized totheexpressionofGAPDHmRNA
and expressed either as relative expression to GAPDH mRNA using
the formulae 2




5 cells) were suspended in phosphate-buffered
saline (PBS) containing 0.1% bovine serum albumin and 0.01%
sodium azide and incubated for 20 min on ice with conjugated
monoclonal antibodies. Specific and isotypic control antibodies
were from BD Biosciences (Le Pont de Claix, France).
Mononuclear cell suspensions were isolated after dissociation of
spleens and draining lymph nodes or from blood after Ficoll
separation as described elsewhere [47]. For membrane staining,
cells were incubated with anti-mouse conjugated antibodies or F4-
80 or B220 conjugated antibodies (BD Biosciences) as described
above. For Foxp3 intracellular staining, cells were incubated in
150 ml/well of Fix/Perm solution overnight at 4uC and then at
4uC for 15 min with permeabilization buffer (Cliniscience,
Montrouge, France), followed by incubation with anti-Foxp3
antibody for 30 min on ice (Miltenyi Biotec, Paris, France). Flow
cytometry was performed on a fluorescence activated cell sorter
(FACSCalibur), and data analysed with the CellquestPro software
(BD, Le Pont de Claix, France).
Measurement of IDO and iNOS Activities
IDO enzyme activity was measured after MSC stimulation with
1000 U/ml IFN-c for 48 hours as reported [46,48].
Because nitric oxide (NO) is quickly converted to NO2 and NO3
in culture medium,NO2 production wasmeasured usinga modified
Griess reagent (Sigma-Aldrich) as described previously [49].
Quantification of cytokines
Enzyme-linked immunosorbent assays (ELISA) were from R&D
Systems or Cliniscience for IL-6. Cytokines and PGE2 were
quantified in culture supernatants from T-cell proliferation assays
or in sera. For analysis of cytokine production by splenocytes or
lymph node cells, 2610
6 cells were seeded in proliferation medium
and stimulated with 10 mg/ml of bCII. Supernatants were
collected either after 24 h for IFN-c and IL-17 or 48 h for the
others. bCII-specific immunoglobulins were quantified using
alkaline phosphatase-labelled anti-mouse IgG1 and anti-mouse
IgG2a antibodies (BD Biosciences) as previously described [50].
T-cell proliferation assay
Splenocytes were obtained after spleen dissociation and lysis of
erythrocytes with an equal volume of ACT solution (155 mM
NH4Cl, 0.1 mM EDTA and 10 mM KHCO3). Lymph nodes
were disaggregated by treatment with 0.1% collagenase D (Roche)
at 37uC for 1 hour. Isolated cells were seeded in triplicates in
100 ml of medium consisted of heat-inactivated FBS-containing
RPMI 1640 supplemented with 0.1 mM non essential amino
acids, 1 mM sodium pyruvate, 20 mM N-2-hydroxyethylpiper-
azine-N’-2-ethanesulfonic acid (HEPES) (Invitrogen) and 50 mM
2-mercaptoethanol (Lonza).
For coculture experiments, 10
5 splenocytes were stimulated with
1 mg/ml concanavalin A (conA) (Sigma-Aldrich). When necessary,
5610
4 MSCs per well (ratio 1/2 of MSC/T cells if not indicated
or 5610
3 MSCs corresponding to ratio 1/20) and/or inhibitors
(indomethacine 5 mM; L-NAME 10 mM, Sigma-Aldrich) were
added. For evaluating the proliferation of T cells isolated from in
vivo experiments, 8610
5 splenocytes or cells from lymph nodes
were stimulated by 5 mg/ml of conA or 1, 5, 25 mg/ml of bCII.
After 3 days, cell proliferation was measured using the
CellTiter-Glo
TM luminescent cell viability assay (Promega,
Charbonnie `res-les-Bains, France).
Arthritis induction and measurement
Adult male DBA/1 mice aged 9–10 weeks were grown in our
animal facilities. All animal experiments complied with the
regulations of the Ethical Committee of the Languedoc-Roussil-
lon. Approval CEEA-LR-1042 (Comite ´R e ´gional d’e ´thique pour
l’expe ´rimentation animale, Languedoc Roussillon). Immunization
was performed as reported in [16] and MSCs (1610
6 cells) were
injected intravenously on day 18 and 24, otherwise indicated.
Signs of arthritis were assessed by measuring the paw swelling of
the hind paw and evaluating the clinical score using the
macroscopic scale as previously described [16]. After sacrifice,
the hind limbs were collected for X-ray and radiological scoring
was performed as described [51].
Histology and immunohistochemistry
The paws were fixed in 4% paraformaldehyde, decalcified
overnight in Rapid Bone Decalcifier (Eurobio, Les Ulis, France)
and processed for routine histology. Histological scoring was
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0, normal; 1, inflammatory infiltrates and synovial hyperplasia; 2,
pannus formation and cartilage erosion; 3, important cartilage
erosion and bone destruction, 4, loss of joint integrity.
Statistical analysis
Statistics were done using the Student t test and for in vivo
experiments, with an impaired Mann-Whitney test to compare
nonparametric data for statistical significance.
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